NASDAQ:DTIL - Precision BioSciences Stock Price, Forecast & News

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DTIL stock has decreased by 4.6% and is now trading at $6.19. View which stocks have been mosted impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Precision BioSciences.

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Precision BioSciences.

Precision BioSciences Inc (NASDAQ:DTIL) posted its quarterly earnings results on Tuesday, March, 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.15. The business had revenue of $6.52 million for the quarter, compared to the consensus estimate of $9.56 million. Precision BioSciences had a negative return on equity of 66.96% and a negative net margin of 417.65%. View Precision BioSciences' earnings history.

8 analysts have issued 12 month price targets for Precision BioSciences' shares. Their forecasts range from $19.00 to $24.00. On average, they anticipate Precision BioSciences' share price to reach $22.17 in the next twelve months. This suggests a possible upside of 258.1% from the stock's current price. View analysts' price targets for Precision BioSciences.

Press coverage about DTIL stock has been trending very negative recently, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Precision BioSciences earned a news sentiment score of -3.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutPrecision BioSciences.

Precision BioSciences saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,957,900 shares, an increase of 18.7% from the February 27th total of 1,650,000 shares. Based on an average daily volume of 519,100 shares, the days-to-cover ratio is currently 3.8 days. Currently, 5.8% of the company's shares are sold short. View Precision BioSciences' Current Options Chain.

Some companies that are related to Precision BioSciences include Regenxbio (RGNX), Editas Medicine (EDIT), Coherus Biosciences (CHRS), I-Mab (BDTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), Beam Therapeutics (BEAM), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Oyster Point Pharma (OYST), Krystal Biotech (KRYS), Orchard Therapeutics (ORTX), Novavax (NVAX), Osiris Therapeutics (OSIR) and AVITA MED LTD/S (AVMXY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Alibaba Group (BABA), Exxon Mobil (XOM), Alector (ALEC), NVIDIA (NVDA), Gilead Sciences (GILD), Gossamer Bio (GOSS), Immunomedics (IMMU), Inovio Pharmaceuticals (INO) and Micron Technology (MU).

(DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Precision BioSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital World Investors (8.00%), FMR LLC (5.18%), ArrowMark Colorado Holdings LLC (3.83%), Alliancebernstein L.P. (3.01%), Franklin Resources Inc. (2.39%) and Franklin Resources Inc. (2.39%). Company insiders that own Precision BioSciences stock include Christopher Heery, Global Strategic Fund Venbio and Tony Dung Ling Yao. View institutional ownership trends for Precision BioSciences.

DTIL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Franklin Resources Inc., Hamilton Lane Advisors LLC, and Barclays PLC. View insider buying and selling activity for Precision BioSciences.

DTIL stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Alliancebernstein L.P., ArrowMark Colorado Holdings LLC, Adams Chetwood Wealth Management LLC, State Street Corp, Victory Capital Management Inc., Victory Capital Management Inc., and Nachman Norwood & Parrott Inc. Company insiders that have bought Precision BioSciences stock in the last two years include Christopher Heery, Global Strategic Fund Venbio, and Tony Dung Ling Yao. View insider buying and selling activity for Precision BioSciences.

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DTIL stock can currently be purchased for approximately $6.19.

Precision BioSciences has a market capitalization of $318.17 million and generates $22.24 million in revenue each year. The company earns $-92,880,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Precision BioSciences employs 127 workers across the globe. View additional information about Precision BioSciences.

The official website for Precision BioSciences is http://www.precisionbiosciences.com/.

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]